GMI
VRTX icon

Greystone Managed Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Greystone Managed Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$6.04M Sell
35,682
-1,071
-3% -$189K 0.37% 79
2019
Q2 		$6.74M Buy
+36,753
New +$6.43M 0.39% 74

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Greystone Managed Investments's VRTX Position: Q3 2019 in Review

Greystone Managed Investments reduced its Vertex Pharmaceuticals (VRTX) stake by 2.9% in Q3 2019, selling an estimated $189K and leaving 35,682 shares worth $6.04M. The position accounts for 0.37% of the portfolio, ranked #79.

Greystone Managed Investments first reported a position in VRTX in Q2 2019 and has held it in 2 quarters since. The position peaked at $6.74M in Q2 2019. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

  • Greystone Managed Investments held 35,682 shares of Vertex Pharmaceuticals worth $6.04M as of Q3 2019.
  • Greystone Managed Investments sold 1,071 Vertex Pharmaceuticals shares in Q3 2019, an estimated $189K.
  • Vertex Pharmaceuticals made up 0.37% of Greystone Managed Investments's portfolio in Q3 2019, its #79 holding.
  • Greystone Managed Investments first reported a position in Vertex Pharmaceuticals in Q2 2019 and has held it in 2 quarters since.
  • Greystone Managed Investments's Vertex Pharmaceuticals position peaked at $6.74M in Q2 2019.
  • 708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Greystone Managed Investments's 13F filing for Q3 2019, filed 5 Nov 2019.